Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Other Accumulated Expenses (2017 - 2025)

Historic Other Accumulated Expenses for Catalyst Pharmaceuticals (CPRX) over the last 10 years, with Q3 2025 value amounting to $842000.0.

  • Catalyst Pharmaceuticals' Other Accumulated Expenses rose 8752.78% to $842000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $842000.0, marking a year-over-year increase of 8752.78%. This contributed to the annual value of $417000.0 for FY2024, which is 1032.26% down from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Other Accumulated Expenses is $842000.0, which was up 8752.78% from $747000.0 recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Other Accumulated Expenses ranged from a high of $2.2 million in Q1 2025 and a low of $372000.0 during Q2 2024
  • Over the past 3 years, Catalyst Pharmaceuticals' median Other Accumulated Expenses value was $465000.0 (recorded in 2023), while the average stood at $788142.9.
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Other Accumulated Expenses crashed by 1032.26% in 2024, and later surged by 10080.65% in 2025.
  • Quarter analysis of 3 years shows Catalyst Pharmaceuticals' Other Accumulated Expenses stood at $465000.0 in 2023, then fell by 10.32% to $417000.0 in 2024, then soared by 101.92% to $842000.0 in 2025.
  • Its Other Accumulated Expenses stands at $842000.0 for Q3 2025, versus $747000.0 for Q2 2025 and $2.2 million for Q1 2025.